Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.
Betacoronavirus
/ immunology
COVID-19
Computational Biology
Coronavirus Infections
/ epidemiology
Drug Development
/ methods
Epitopes, B-Lymphocyte
/ immunology
Epitopes, T-Lymphocyte
/ immunology
Humans
Nucleocapsid Proteins
/ immunology
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ immunology
Vaccines, Subunit
/ immunology
Viral Vaccines
/ immunology
B-cell epitopes
Bioinformatics
COVID-19
SARS-CoV-2
T-cell epitopes
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
01
05
2020
revised:
07
06
2020
accepted:
22
06
2020
pubmed:
20
7
2020
medline:
25
8
2020
entrez:
20
7
2020
Statut:
ppublish
Résumé
The beginning of 2020 was marked as the emergence of a COVID-19 outbreak caused by a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no vaccine or approved treatment for this infectious virus so the invention of an efficient vaccine is certainly a high priority. Some studies have employed several techniques to facilitate the combination of the immunoinformatics approach and comparative genomic approach in order to determine the potential peptides for designing the T-cell epitope-based peptide vaccine using the 2019-nCoV envelope protein as a target. Via screening the bioimmunoinformatic SARS-CoV2 derived B-cell and T-cell epitopes within the basic immunogenic of SARS-CoV2 proteins, we presented a set of inferred B-cell and T-cell epitopes from the spike (S) and nucleocapsid (N) proteins with high antigenicity and without allergenic property or toxic effects. Our findings provide a screened set of epitopes that can be introduced as potential targets for developing peptide vaccines against the SARS-CoV-2 virus.
Identifiants
pubmed: 32683296
pii: S1567-5769(20)31382-5
doi: 10.1016/j.intimp.2020.106738
pmc: PMC7321027
pii:
doi:
Substances chimiques
Epitopes, B-Lymphocyte
0
Epitopes, T-Lymphocyte
0
Nucleocapsid Proteins
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Subunit
0
Viral Vaccines
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106738Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Microb Pathog. 2020 Aug;145:104236
pubmed: 32376359
Chem Sci. 2016 Feb 1;7(2):842-854
pubmed: 28791117
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
BMC Infect Dis. 2013 Jun 24;13:288
pubmed: 23799878
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Lancet. 2003 Oct 25;362(9393):1353-8
pubmed: 14585636
Virusdisease. 2020 Mar;31(1):13-21
pubmed: 32206694
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Cell Res. 2003 Jun;13(3):141-5
pubmed: 12862314
Am J Infect Control. 2020 Jun;48(6):713
pubmed: 32171622
J Med Virol. 2020 Jun;92(6):618-631
pubmed: 32108359
Environ Res. 2020 May;184:109263
pubmed: 32113025
EBioMedicine. 2020 May;55:102768
pubmed: 32344202
J Med Virol. 2020 May;92(5):495-500
pubmed: 32022276
Virus Res. 2020 Oct 15;288:198082
pubmed: 32621841
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
J Virol. 2020 Feb 14;94(5):
pubmed: 31826992
Ecotoxicol Environ Saf. 2018 Aug 30;158:171-181
pubmed: 29684747